Kalaris Therapeutics, Inc.
KLRS
$3.41
-$0.06-1.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -20.96% | 16.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.67% | 9.55% | |||
| Operating Income | -4.67% | -9.55% | |||
| Income Before Tax | -6.07% | -8.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -6.07% | -8.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -6.07% | -8.58% | |||
| EBIT | -4.67% | -9.55% | |||
| EBITDA | -4.68% | -9.56% | |||
| EPS Basic | -5.75% | 10.96% | |||
| Normalized Basic EPS | -5.73% | 10.96% | |||
| EPS Diluted | -5.75% | 10.96% | |||
| Normalized Diluted EPS | -5.73% | 10.96% | |||
| Average Basic Shares Outstanding | 0.31% | 21.95% | |||
| Average Diluted Shares Outstanding | 0.31% | 21.95% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||